Amoéba Funding: How Much Did They Raise & Key Investors

How Much Did Amoéba Raise?
Funding & Key Investors

Amoéba, a pioneer in the environmental health sector, has successfully secured a major strategic investment, bringing its total capital accumulation to $4.6M. This latest infusion of $4.6M underscores the market's growing confidence in the company's proprietary biological solutions. By leveraging unique microbial technology, the firm is positioning itself as a critical player in the transition toward sustainable industrial practices, moving away from traditional chemical-heavy methodologies.

The recent financing round, finalized on March 25, 2026, serves as a pivotal milestone for the Lyon-based enterprise. As the company scales its operations, this capital injection provides the necessary runway to accelerate the commercial deployment of its biological treatments across diverse sectors, including industrial water systems and advanced wound care applications.

What is Amoéba?

Amoéba

Business Services

Research & Development

Manufacturing

Amoéba operates at the intersection of biotechnology and environmental safety, specializing in the development of innovative biocides derived from the microorganism Willaertia magna. Unlike conventional chemical treatments that often carry significant environmental and health risks, Amoéba's biological approach offers a potent, natural alternative for controlling harmful bacteria such as legionella. The company's core value proposition lies in its ability to provide high-efficacy microbial control for industrial cooling towers and other critical infrastructure, effectively mitigating health hazards without the ecological footprint associated with synthetic alternatives. By integrating its technology into existing industrial workflows, Amoéba is redefining standards for safety and sustainability in water management and plant protection.

How much funding has Amoéba raised?

Amoéba has raised a total of $4.6M across 1 funding round:

2026

Stock/Share Issuance

$4.6M

Stock/Share Issuance (2026): $4.6M with participation from Vatel Capital

Key Investors in Amoéba

Vatel Capital

Vatel Capital is a French investment firm specializing in asset management and tax-efficient financial strategies, providing growth capital to innovative companies.

What's next for Amoéba?

With this major enterprise-level funding, Amoéba is poised to transition from a research-intensive development phase into a period of aggressive market expansion. The strategic roadmap likely includes scaling production capabilities to meet the rising demand for chemical-free biocides and expanding its regulatory footprint in international markets. Furthermore, the company is expected to deepen its R&D efforts to explore new applications for Willaertia magna, potentially diversifying its portfolio into broader medical and agricultural sectors. As the global regulatory landscape continues to tighten around chemical usage, Amoéba's sustainable, nature-based solutions are well-positioned to capture significant market share, establishing the firm as a leader in the next generation of environmental health technologies.

See full Amoéba company page

See More Financial Insights